Global Intra Abdominal Infection Market to be Driven by Development of New Drugs13 Apr 2016
A new research report, titled “Intra Abdominal Infection Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” by Transparency Market Research talks about the market in great detail, including an overview, key products, major geographical segments, and competitive landscape. The major drivers, barriers, and current trends are also discussed in the scope of the research report. The historical data and estimates of the global market for intra abdominal infection therapeutics are included in the research study with the assistance of tables, charts, and infographics.
Browse Full Report: http://www.transparencymarketresearch.com/intra-abdominal-infection.html
Intra abdominal infections are a very common cause of mortalities worldwide. Intra abdominal infections include food poisoning, intra abdominal abscess, peritonitis, diverticulitis, appendicitis, and pelvic inflammatory disease. The major cause of this condition is a post-surgical infection. It can also be caused due to a ruptured appendix, inflammatory bowel disease, and intestinal infections. Some of the common symptoms of intra abdominal infection are chills, nausea, abdominal pain, vomiting, lack of appetite, fever, diarrhea, and rectal tenderness. The increasing market penetration, thanks to the availability of low-cost drugs, is projected to augment the growth of the market in the forecast period.
These diseases are diagnosed by abdominal computed tomography (CT), X-rays, blood tests, and ultrasound. Some of the major antibiotics that are prescribed for patients suffering from intra abdominal infections are aerobic coverage and anaerobic coverage. The aerobic coverage segment is further sub-classified into quinolones, beta lactums, vancomycine, and aminoglycosides. On the other hand, the anaerobic coverage segment is further sub-categorized into clindamycin, chloramphenicol, and metronidazole.
Furthermore, the research report has classified the global market for intra abdominal infection therapeutics on the basis of geography into North America, Asia Pacific, Europe, and Rest of the World. The market share and estimated figures of each region have been included in the research study. Pharmaceutical companies around the world are taking constant efforts to develop and introduce new drugs for intra abdominal infection treatment. Some of the prominent companies that are conducting clinical trials for intra abdominal infections are Merck Sharp & Dohme Corp., Pfizer, and Tetraphase Pharmaceuticals, Inc. With the introduction of new drugs and acquisition of regulatory approvals, the global intra abdominal infection market is estimated to grow at a significant rate in the next few years.
The research study further covers the vendor analysis and competitive scenario of the global market for intra abdominal infection therapeutics, including the company profile, inception details, business strategies, SWOT analysis, financial overview, and recent developments of major players in the market. The prominent players operating in the global intra abdominal infection market include Aurobindo Pharma Ltd., Merck & Co., Inc., Atox Bio Inc., Teva, AstraZeneca PLC, Dr. Reddys Labs Ltd, and Pfizer, Inc.
Download PDF Report Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2858
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY - 12207